In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.
Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...
We're hardwired to crave fat and sugar. This drive for calorie-dense foods is a big part of how our ancient ancestors ...
Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
Dr. Corey L. Hartman tells ESSENCE how this prescription can have long-term effects not just the body—but also on our skin.